InterCure (INCR.TA) Saham Harga

InterCure Ltd is primarily active in the medical cannabis industry.

The main competitors of InterCure Ltd in the market include established companies such as GW Pharmaceuticals, Tilray Inc., and Canopy Growth Corporation. These companies also operate within the medical cannabis industry and compete with InterCure in terms of product development, market share, and innovation. InterCure aims to differentiate itself by offering unique medical cannabis products and focusing on research and development to provide enhanced solutions for patients. Despite facing competition from various industry players, InterCure Ltd continues to strive for growth and maintain its market position through strategic partnerships and constant advancements in the field.

InterCure Ltd, a leading Israeli medical cannabis company, was founded in 2011. With a focus on improving patients' quality of life, InterCure is dedicated to research, development, production, and distribution of medical cannabis products. The company operates under the brand name "Canndoc" and holds a distinctive presence in both domestic and international markets. With a commitment to excellence, InterCure continuously strives to enhance patient care through its state-of-the-art cultivation facilities, advanced research initiatives, and partnerships with renowned international experts. With a rich history of innovation and a commitment to improving global healthcare, InterCure Ltd has established itself as a prominent player in the medical cannabis industry.

InterCure Ltd has achieved several significant milestones since its establishment. The company successfully developed and launched the innovative RESPeRATE device, a non-drug, FDA-cleared solution for hypertension. Additionally, InterCure Ltd has expanded its global presence, establishing partnerships and distribution channels in various markets. The company continues to enhance its product portfolio, offering advanced technologies and solutions to address various medical conditions. InterCure Ltd has also experienced notable financial growth and recognition, attracting investments and receiving prestigious awards for its advancements in healthcare. Overall, the company's milestones highlight its commitment to revolutionizing medical treatments and improving patients' well-being.

InterCure Ltd is primarily present in Israel, the United States, Canada, and Germany.

InterCure Ltd represents a strong commitment to promoting wellness and improving quality of life. The company values include innovation, integrity, and excellence. InterCure focuses on developing and commercializing therapeutic solutions that address unmet medical needs, particularly in the fields of respiratory disease and wellness. The corporate philosophy of InterCure revolves around advancing healthcare through cutting-edge technologies and research. With a dedicated team, InterCure aims to revolutionize the way illnesses are managed and to provide accessible treatments for better health outcomes. interCure Ltd is driven by its mission to enhance well-being and empower individuals to live healthier, more fulfilling lives.

Analis saat ini menetapkan target harga rata-rata 7,14 ILS untuk saham InterCure (median: 7,14 ILS), yaitu -47,8 % terhadap harga terbaru. Konsensus didasarkan pada 7 peringkat analis.

InterCure Target Harga Analis 2026

7 analis saat ini menilai saham InterCure: 6 merekomendasikan beli, 1 tahan, dan 0 jual. Untuk 2026, analis memperkirakan InterCure menghasilkan pendapatan 574,00 Juta. ILS dan laba per saham 1,70 ILS.

InterCure Target Harga Analis 2026

Dengan kurs saat ini, saham InterCure diperdagangkan pada 3,92 EUR (13,69 ILS).

Saham InterCure (INCR.TA) tercatat di 2 bursa, termasuk: NASDAQ (INCR).

InterCure Ltd was founded in 2000 to offer innovative digital health solutions. The company is based in Israel and provides various products and services targeting telemedicine, chronic diseases, and lifestyle management. Telemedicine InterCure offers an award-winning telemedicine platform called "CardioCare". This platform allows doctors to diagnose, treat, and monitor patients with high blood pressure without them having to come to a clinic. The platform includes a wireless blood pressure monitor connected to the patient's "CardioCare" app. By using this technology, the doctor can monitor the patient's blood pressure in real time and adjust the medication accordingly. Chronic diseases InterCure also offers products for managing chronic diseases such as asthma, diabetes, and COPD. The "RespeRate" is a breathing training device designed for patients with respiratory diseases. The device helps regulate breathing rhythm and patterns to improve the quality of breath and reduce symptoms. Lifestyle management Another product offered by InterCure is "Relaxing Moments". This app includes audio and video content for stress management and relaxation. The app was developed in collaboration with leading relaxation and stress reduction experts and includes exercises for breathing, meditation, and mindfulness. InterCure has also partnered with the company "Glucovation" to develop a "Smart Patch" for diabetics. This patch continuously measures blood glucose levels and sends this data to an app on the patient's smartphone. Through these continuous measurements, the patient can adjust medication in real time. Overall, InterCure offers a wide range of products and services aimed at improving patients' health and well-being. By utilizing digital technology, telemedicine, and collaborating with experts in various fields, InterCure supports patients in managing chronic diseases, relaxation, and disease prevention.

Pendapatan diperkirakan dari InterCure adalah 574,00 Juta. ILS. Angka ini didasarkan pada data keuangan terkini dan mencerminkan kinerja bisnis perusahaan.

Laba diperkirakan dari InterCure adalah 78,13 Juta. ILS. Laba bersih mencerminkan profitabilitas perusahaan setelah mengurangi semua biaya.

Rasio harga-terhadap-pendapatan (PER) InterCure saat ini adalah 8,04. PER membandingkan harga saham saat ini dengan laba per saham dan membantu investor menilai valuasi saham InterCure.

Rasio harga-terhadap-penjualan (PSR) InterCure saat ini adalah 1,09. PSR membandingkan kapitalisasi pasar dengan pendapatan tahunan dan berfungsi sebagai metrik valuasi untuk saham InterCure.

Skor Kualitas AlleAktien untuk InterCure adalah 2/10.

ISIN dari InterCure adalah IL0011063760. ISIN (International Securities Identification Number) adalah identifikasi unik global untuk sekuritas.

WKN dari InterCure adalah A1CZA8. WKN (Wertpapierkennnummer) adalah kode identifikasi sekuritas Jerman enam digit.

Ticker dari InterCure adalah INCR.TA. Simbol ticker digunakan untuk memperdagangkan saham InterCure di bursa saham.